Overview

A Study for Patients That Have Been Previously Been Treated in Waldenstrom's Macroglobulinemia or Multiple Myeloma

Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
To determine whether further study of single-agent enzastaurin is warranted in patients with previously treated Waldenstrom's Macroglobulinemia or Multiple Myeloma based on response.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company